List of nationally authorised medicinal products
|
|
- Edith Blake
- 5 years ago
- Views:
Transcription
1 8 March 2018 EMA/182904/2018 Human Medicines Evaluation Division Active substance(s): fluticasone propionate / formoterol fumarate dihydrate Procedure No.: PSUSA/ / Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website An agency of the European Union European Medicines Agency, Reproduction is authorised provided the source is acknowledged.
2 National Number Abriff 125 microgrammi/5 Abriff 125 microgrammi/5 Abriff 125 microgramos/5 microgramos inhalación Abriff 250 microgrammi/10 Abriff 250 microgrammi/10 Abriff 250 microgramos/10 microgramos inhalación, /H/4379/ /M MUNDIPHARMA /H/4379/ MUNDIPHARMA /H/4379/ MUNDIPHARMA /H/4379/ /M MUNDIPHARMA /H/4379/ MUNDIPHARMA /H/4379/ MUNDIPHARMA EMA/182904/2018 Page 2/17
3 National Number Abriff 50 microgrammi/5 Abriff 50 microgrammi/5 Abriff 50 microgramos/5 microgramos inhalación, Abriff 125 microgram/5 microgram per actuation Abriff 250 microgram/10 micro gram per actuation Abriff 50 microgram/5 microgr am per actuation AFFERA 125 /H/4379/ /M MUNDIPHARMA /H/4379/ MUNDIPHARMA /H/4379/ MUNDIPHARMA /H/4379/002 PL 16950/0189 NAPP PHARMACEUTICALS /H/4379/003 PL 16950/0190 NAPP PHARMACEUTICALS /H/4379/001 PL 16950/0188 NAPP PHARMACEUTICALS /H/4378/ MUNDIPHARMA FR EMA/182904/2018 Page 3/17
4 National Number Affera 125 microgrammi/5 Affera 125 microgramos/5 microgramos inhalación, AFFERA 250 microgrammes/10 Affera 250 microgrammi/10 Affera 250 microgramos/10 microgramos inhalación, AFFERA 50 /H/4378/ /M MUNDIPHARMA /H/4378/ MUNDIPHARMA /H/4378/ MUNDIPHARMA FR /H/4378/ /M MUNDIPHARMA /H/4378/ MUNDIPHARMA /H/4378/ MUNDIPHARMA FR EMA/182904/2018 Page 4/17
5 National Number Affera 50 microgrammi/5 Affera 50 microgramos/5 microgramos inhalación, affera 125 Mikrogramm/5 Affera 125 microgram/5 microg ram per actuation affera 250 Mikrogramm/10 Affera 250 microgram/10 micro gram per actuation /H/4378/ /M MUNDIPHARMA /H/4378/ MUNDIPHARMA /H/4378/ MUNDIPHARMA GMBH DE /H/4378/002 PL 16950/0186 NAPP PHARMACEUTICALS /H/4378/ MUNDIPHARMA GMBH DE /H/4378/003 PL 16950/0187 NAPP PHARMACEUTICALS affera 50 /H/4378/ MUNDIPHARMA GMBH DE EMA/182904/2018 Page 5/17
6 National Number Mikrogramm/5 Affera 50 microgram/5 microgr am per actuation 125 mcg/5 mcg, 125 microgram I 5 microgram, aerosol, suspensie 125 microgram/ 5 microgram I dosis aerosol, suspensie 125 microgram/5 microgram per metered dose 125 micrograme /5 micrograme suspensie de inhalat presurizată 125 microgrammes, /H/4378/001 PL 16950/0185 NAPP PHARMACEUTICALS /H/2872/ /DC MUNDIPHARMA COMM VA LU /H/2872/002 BE MUNDIPHARMA COMM VA BE /H/2872/001 RVG MUNDIPHARMA PHARMACEUTICALS BV /H/2872/002 PA 1688/13/2 MUNDIPHARMA PHARMACEUTICALS LIMED /H/2872/ /2013/01 MUNDIPHARMA G.M.B.H RO /H/2872/002 BE MUNDIPHARMA COMM VA BE NL IE EMA/182904/2018 Page 6/17
7 National Number FLUTIFORM microgramos/5 microgramos/inhalación, 125 mikrogram/ 5 mikrogram per dose, inhalasjonsaerosol, suspensjon 125 mikrogram/5 mikrogram per puff, inhalationsspray, 125 Mikrogramm/5 125 mikrogramov/5 mikrogramov 125 mikrogramů/5 mikrogramů v jedné /H/2872/ MUNDIPHARMA FR /H/2872/ MUNDIPHARMA /H/2872/ MUNDIPHARMA AS. NO /H/2872/ MUNDIPHARMA AB SE /H/2872/ MUNDIPHARMA GELLSCHAFT M.B.H. /H/2872/002 14/0357/12-S MUNDIPHARMA G.M.B.H SK /H/2872/002 14/554/12-C MUNDIPHARMA G.M.B.H CZ AT EMA/182904/2018 Page 7/17
8 National Number dávce, suspenze k inhalaci v tlakovém obalu 125 microgramas/5 micr ogramas suspensão pressurizada para inalação 125 mikrog/5 mikrog/an nos Inhalaatiosumute, suspensio 125 míkrógrömm/5 míkr ógrömm í úðaskammti innúðalyf, dreifa 125 μικρογραμμάρια/5 μικρογραμμάρια ανά ψεκασμό, εναιώρημα για εισπνοή υπό πίεση 250 mcg/10 mcg,. 250 microgram / 10 microgram I dosis aerosol, suspensie 250 microgram I 10 microgram, aerosol, suspensie 250 microgram/10 microgram per metered dose pressurised inhalation, /H/2872/ MUNDIPHARMA PHARMACEUTICALS /H/2872/ MUNDIPHARMA OY FI /H/2872/002 IS/1/12/096/02 NORPHARMA A/S IS /H/2872/ MUNDIPHARMA PHARMACEUTICALS /H/2872/ /DC MUNDIPHARMA COMM VA LU /H/2872/003 RVG MUNDIPHARMA PHARMACEUTICALS BV /H/2872/003 BE MUNDIPHARMA COMM VA BE /H/2872/003 PA 1688/13/3 MUNDIPHARMA PHARMACEUTICALS LIMED PT CY NL IE EMA/182904/2018 Page 8/17
9 National Number 250 micrograme/10 micrograme suspensie de inhalat presurizata 250 microgrammes/10 microgrammes, FLUTIFORM 250 microgrammes/ microgramos/10 microgramos/inhalación, 250 mikrogram/ 10 mikrogram per dose, inhalasjonsaerosol, suspensjon 250 mikrogram/10 mikrogram 250 mikrogram/10 mikrogram per puff, inhalationsspray, /H/2872/ /2013/01 MUNDIPHARMA G.M.B.H RO /H/2872/003 BE MUNDIPHARMA COMM VA BE /H/2872/ MUNDIPHARMA FR /H/2872/ MUNDIPHARMA /H/2872/ MUNDIPHARMA AS. NO /H/2872/003 14/0358/12-S MUNDIPHARMA G.M.B.H SK /H/2872/ MUNDIPHARMA AB SE EMA/182904/2018 Page 9/17
10 National Number 250 Mikrogramm/ mikrogramů/10 mikrogramů v jedné dávce, suspenze k inhalaci v tlakovém obalu 250 microgramas/10 mic rogramas suspensão pressurizada para inalação 250 mikrog/10 mikrog/a nnos Inhalaatiosumute, suspensio 250 míkrógrömm/10 mík rógrömm í úðaskammti innúðalyf, dreifa 250 μικρογραμμάρια/10 μικρογραμμάρια ανά ψεκασμό, εναιώρημα για εισπνοή υπό πίεση 50 mcg/5 mcg, 50 microgram / 5 microgram, aërosol, /H/2872/ MUNDIPHARMA GELLSCHAFT M.B.H. /H/2872/003 14/555/12-C MUNDIPHARMA G.M.B.H CZ /H/2872/ MUNDIPHARMA PHARMACEUTICALS /H/2872/ MUNDIPHARMA OY FI /H/2872/003 IS/1/12/096/03 NORPHARMA A/S IS /H/2872/ MUNDIPHARMA PHARMACEUTICALS /H/2872/ MUNDIPHARMA COMM VA LU /H/2872/001 BE MUNDIPHARMA COMM VA BE AT PT CY EMA/182904/2018 Page 10/17
11 National Number suspensie 50 microgram I 5 microgram I dosis aerosol, suspensie 50 microgram/5 microgram per metered dose 50 micrograme /5 micrograme suspensie de inhalat presurizată 50 microgrammes, FLUTIFORM microgramos/5 microgramos/inhalación, 50 mikrogram/ 5 mikrogram per dose, inhalasjonsaerosol, suspensjon /H/2872/001 RVG MUNDIPHARMA PHARMACEUTICALS BV /H/2872/001 PA 1688/13/1 MUNDIPHARMA PHARMACEUTICALS LIMED /H/2872/ /2013/01 MUNDIPHARMA G.M.B.H RO /H/2872/001 BE MUNDIPHARMA COMM VA BE /H/2872/ MUNDIPHARMA FR /H/2872/001/E/ MUNDIPHARMA /H/2872/ MUNDIPHARMA AS. NO 50 /H/2872/ MUNDIPHARMA AB SE NL IE EMA/182904/2018 Page 11/17
12 National Number mikrogram/5 mikrogram per puff, inhalationsspray, 50 Mikrogramm/5 50 mikrogramov/5 mikrogramov 50 mikrogramů/5 mikrogramů v jedné dávce, suspenze k inhalaci v tlakovém obalu 50 μικρογραμμάρια/5 μικρογραμμάρια ανά ψεκασμό, εναιώρημα για εισπνοή υπό πίεση. 50 microgramas/5 micro gramas suspensão pressurizada para inalação 50 mikrog/5 mikrog/ann os Inhalaatiosumute, suspensio 50 míkrógrömm/5 míkró grömm í úðaskammti /H/2872/ MUNDIPHARMA GELLSCHAFT M.B.H. /H/2872/001 14/0356/12-S MUNDIPHARMA G.M.B.H SK /H/2872/001 14/553/12-C MUNDIPHARMA G.M.B.H CZ /H/2872/ MUNDIPHARMA PHARMACEUTICALS /H/2872/ MUNDIPHARMA PHARMACEUTICALS /H/2872/ MUNDIPHARMA OY FI /H/2872/001 IS/1/12/096/01 NORPHARMA A/S IS AT CY PT EMA/182904/2018 Page 12/17
13 National Number innúðalyf, dreifa, (125 mikrogramów + 5 mikrogramów)/dawke inhalacyjna, aerozol inhalacyjny, zawiesina, (250 mikrogramów + 10 mikrogramów)/dawkę inhalacyjną, aerozol inhalacyjny, zawiesina, (50 mikrogramów + 5 mikrogramów)/dawke inhalacyjna, aerozol inhalacyjny, zawiesina, inhalationsspray,, inhalationsspray,, inhalationsspray, 125 microgram/5 microgram per actuation pressurised inhalation, flutiform 125 Mikrogramm/5 /H/2872/ NORPHARMA A/S PL /H/2872/ NORPHARMA A/S PL /H/2872/ NORPHARMA A/S PL /H/2872/ NORPHARMA A/S DK /H/2872/ NORPHARMA A/S DK /H/2872/ NORPHARMA A/S DK /H/2872/002 PL 16950/0168 NAPP PHARMACEUTICALS /H/2872/ MUNDIPHARMA GMBH DE EMA/182904/2018 Page 13/17
14 National Number 250 microgram/10 microgram per actuation. flutiform 250 Mikrogramm/10 50 microgram/5 microgram per actuation pressurised inhalation, flutiform 50 Mikrogramm/5 o 125 microgrammi/5 o 125 microgrammi/5 o 250 microgrammi/10 /H/2872/003 PL 16950/0190 NAPP PHARMACEUTICALS /H/2872/ MUNDIPHARMA GMBH DE /H/2872/001 PL 16950/0167 NAPP PHARMACEUTICALS /H/2872/ MUNDIPHARMA GMBH DE /H/2872/ MUNDIPHARMA /H/2872/ MUNDIPHARMA /H/2872/ MUNDIPHARMA EMA/182904/2018 Page 14/17
15 National Number o 250 microgrammi/10 o 50 microgrammi/5 o 50 microgrammi/5 Iffeza 125 microgram / 5 microgram per dosis, aerosol, suspensie Iffeza 125 microgrammes, IFFEZA 125 /H/2872/ MUNDIPHARMA /H/2872/ MUNDIPHARMA /H/2872/ MUNDIPHARMA /H/4015/002 BE MUNDIPHARMA COMM VA BE /H/4015/002 BE MUNDIPHARMA COMM VA BE /H/4015/ MUNDIPHARMA FR EMA/182904/2018 Page 15/17
16 National Number Iffeza 250 microgram / 10 microgram per dosis, aerosol, suspensie Iffeza 250 microgrammes/10 microgrammes, IFFEZA 250 microgrammes/10 Iffeza 50 microgram / 5 microgram per dosis, aerosol, suspensie Iffeza 50 microgrammes, IFFEZA 50 ФЛУТИФОРМ 125 микрограма/5 микрограма на /H/4015/003 BE MUNDIPHARMA COMM VA BE /H/4015/003 BE MUNDIPHARMA COMM VA BE /H/4015/ MUNDIPHARMA FR /H/4015/001 BE MUNDIPHARMA COMM VA BE /H/4015/001 BE MUNDIPHARMA COMM VA BE /H/4015/ MUNDIPHARMA FR /H/2872/002/DC MUNDIPHARMA G.M.B.H BG EMA/182904/2018 Page 16/17
17 National Number впръскване, суспензия под налягане за инхалация ФЛУТИФОРМ 250 микрограма/10 микрограма на впръскване, суспензия под налягане за инхалация ФЛУТИФОРМ 50 микрограма/5 микрограма на впръскване, суспензия под налягане за инхалация /H/2872/003/DC MUNDIPHARMA G.M.B.H BG /H/2872/001/DC MUNDIPHARMA G.M.B.H BG EMA/182904/2018 Page 17/17
List of nationally authorised medicinal products
28 September 2017 EMA/658449/2017 Human Medicines Evaluation Division Active substance: olodaterol Procedure no.: PSUSA/00010245/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
8 March 2018 EMA/182668/2018 Human Medicines Evaluation Division Active substance(s): triamcinolone (topical and nasal formulations) Procedure No.: PSUSA/00003017/201707 30 Churchill Place Canary Wharf
More informationList of nationally authorised medicinal products
10 September 2015 EMA/677092/2015 Procedure Management and Committees Support Active substance: glatiramer Procedure no.: PSUSA/00001529/201411 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
27 October 2016 EMA/719205/2016 Human Medicines Evaluation Division Active substance: ethinylestradiol / gestodene (except for transdermal application) Procedure no.: PSUSA/00001308/201603 30 Churchill
More informationList of nationally authorised medicinal products
28 September 2017 EMA/639167/2017 Human Medicines Evaluation Division Active substance: zanamivir Procedure no.: PSUSA/00003141/201701 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
10 September 2015 EMA/612853/2015 Procedure Management and Committees Support Active substance: tobramycin (nebuliser solution) Procedure no.: PSUSA/00009316/201412 30 Churchill Place Canary Wharf London
More informationList of nationally authorised medicinal products
6 September 2018 EMA/615391/2018 Human Medicines Evaluation Division Active substance: tobramycin (nebuliser solution) (apart from centrally authorised product) Procedure no.: PSUSA/00009316/201712 30
More informationList of nationally authorised medicinal products
11 October 2017 EMA/784453/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): ipratropium / salbutamol Procedure No.: PSUSA/00001781/201701 30
More informationList of nationally authorised medicinal products
1 September 2017 EMA/580096/2017 Human Medicines Evaluation Division Active substance: terbutaline Procedure no.: PSUSA/00002897/201612 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
26 October 2017 EMA/690754/2017 Human Medicines Evaluation Division Active substance: fish oil / olive oil / soybean oil / triglycerides mediumchain Procedure no.: PSUSA/00010223/201702 30 Churchill Place
More informationList of nationally authorised medicinal products
21 June 2017 EMA/610895/2017 Human Medicines Evaluation Division Active substance: felbamate Procedure no.: PSUSA/00010155/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
10 September 2015 EMA/622830/2015 Procedure Management and Committees Support Active substance: azelastine Procedure no.: PSUSA/00000277/201412 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
14 April 2016 EMA/284169/2016 Procedure Management and Committees Support Active substance: influenza vaccine (split virion, inactivated) (non centrally products) Procedure no.: PSUSA/00010298/201508 30
More informationList of nationally authorised medicinal products
12 January 2017 EMA/36356/2017 Human Medicines Evaluation Division Active substance: hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine Procedure no.: PSUSA/00001696/201605
More informationList of nationally authorised medicinal products
12 July 2018 EMA/497430/2018 Human Medicines Evaluation Division Active substance: tafluprost / timolol Procedure no.: PSUSA/00010324/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
30 November 2017 EMA/817337/2017 Human Medicines Evaluation Division Active substance: Itraconazole Procedure no.: PSUSA/00001798/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
11 January 2018 EMA/24585/2018 Human Medicines Evaluation Division Active substance: esomeprazole / naproxen Procedure no.: PSUSA/00001270/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
01 December 2016 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00002591/201604 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile
More informationList of nationally authorised medicinal products
30 November 2017 EMA/812360/2017 Human Medicines Evaluation Division Active substance(s): mupirocin Procedure No.: PSUSA/00002096/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
11 October 2017 EMA/691535/2017 Human Medicines Evaluation Division Active substance: Haemophilus type b conjugate vaccines Procedure no.: PSUSA/00001584/201702 30 Churchill Place Canary Wharf London E14
More informationList of nationally authorised medicinal products
5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationEuropean Medicines Agency decision
EMA/497687/2017 European Medicines Agency decision P/0245/2017 of 4 September 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for
More informationList of nationally authorised medicinal products
28 September EMA/662335/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): levosalbutamol, salbutamol Procedure No.: PSUSA/00010330/201701 30
More informationList of nationally authorised medicinal products
09 June 2017 EMA/36849/2017 Human Medicines Evaluation Division Active substance(s): brimonidine / timolol Procedure No.: PSUSA/00000431/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
29 November 2018 EMA/880324/2018 Human Medicines Evaluation Division Active substance: enalapril Procedure no.: PSUSA/00001211/201803 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
17 May 2018 EMA/303456/2018 Human Medicines Evaluation Division Active substance: bromazepam Procedure no.: PSUSA/00000435/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
13 September 2017 EMA/706786/2017 Human Medicines Evaluation Division Active substance: Octenidine dihydrochloride / phenoxyethanol Procedure no.: PSUSA/00002199/201701 30 Churchill Place Canary Wharf
More informationList of nationally authorised medicinal products
12 April 2018 EMA/231137/2018 Human Medicines Evaluation Division Active substance: fluvoxamine Procedure no.: PSUSA/00001458/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
1 December 2016 EMA/750653/2016 Human Medicines Evaluation Division Active substance: valganciclovir Procedure no.: PSUSA/00003089/201603 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
06 July 2017 EMA/436040/2017 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00001815/201610 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20
More informationList of nationally authorised medicinal products
5 May 2017 EMA/288255/2017 Human Medicines Evaluation Division Active substance: pilocarpine (ophthalmic formulation) Procedure no.: PSUSA/00002410/201608 30 Churchill Place Canary Wharf London E14 5EU
More informationList of nationally authorised medicinal products
08 March 2018 EMA/170163/2018 Human Medicines Evaluation Division Active substance: enalapril / hydrochlorothiazide Procedure no.: PSUSA/00001212/201707 30 Churchill Place Canary Wharf London E14 5EU United
More informationList of nationally authorised medicinal products
30 November 2017 EMA/817351/2017 Human Medicines Evaluation Division Active substance: Lidocaine / prilocaine (not centrally authorised product) Procedure no.: PSUSA/00001867/201703 30 Churchill Place
More informationList of nationally authorised medicinal products
29 September 2017 EMA/658556/2017 Procedure Management and Committees Support Active substance: loratadine Procedure no.: PSU/00001907/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
30 November 2017 EMA/795271/2017 Human Medicines Evaluation Division Active substance: vinorelbine Procedure no.: PSUSA/00003124/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
6 September 2018 EMA/619619/2018 Human Medicines Evaluation Division Active substance: haemophilus influenzae / klebsiella ozaenae / klebsiella pneumoniae / moraxella catarrhalis / staphylococcus aureus
More informationInitial (Full) Marketing Authorisation application accelerated assessment timetables
30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European
More informationList of nationally authorised medicinal products
20 July 2016 EMA/270645/2015 Procedure Management and Committees Support Active substance: apomorphine Procedure no.: PSUSA/00000227/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
6 September 2018 EMA/608492/2018 Human Medicines Evaluation Division Active substance: betahistine Procedure no.: PSUSA/00000389/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
12 April 2018 EMA/382206/2018 Human Medicines Evaluation Division Active substance(s): naproxen Procedure No.: PSUSA/00002125/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
7 July 2016 EMA/437334/2016 Procedure Management and Committees Support Division Active substance: Terazosin Procedure no.: PSUSA/00002895/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationEuropean Medicines Agency decision
EMA/574564/2017 European Medicines Agency decision P/0278/2017 of 4 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for Japanese encephalitis vaccine (inactivated,
More informationEuropean Medicines Agency decision
EMA/357972/2017 European Medicines Agency decision P/0173/2017 of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for colistimethate sodium (Colobreathe), (EMEA-000176-PIP01-07-M05)
More informationPackage leaflet: Information for the patient. Duohal 25 micrograms /125 micrograms /dose pressurised inhalation, suspension
Package leaflet: Information for the patient Duohal 25 micrograms /125 micrograms /dose pressurised inhalation, suspension Duohal 25 micrograms /250 micrograms /dose pressurised inhalation, suspension
More informationCommission. Product. Notification. Decision. Issued 2 / affected 3 amended on 18/05/2018 PL. 15/03/2018 n/a
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
More informationEuropean Medicines Agency decision
EMA/120432/2017 European Medicines Agency decision P/0069/2017 of 3 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (EMEA-001501-PIP01-13-M04) in
More informationList of nationally authorised medicinal products
12 July 2018 EMA/462856/2018 Human Medicines Evaluation Division Active substance: econazole, econazole nitrate / triamcinolone acetonide, econazole nitrate / zinc oxide Procedure no.: PSUSA/00001195/201711
More informationEuropean Medicines Agency decision
EMA/741983/2016 European Medicines Agency decision P/0324/2016 of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta), (EMEA-000498-PIP01-08-M06)
More informationEuropean Medicines Agency decision
EMA/38339/2017 European Medicines Agency decision P/0021/2017 of 3 February 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (EMEA- 001501-PIP02-13-M02)
More informationEuropean Medicines Agency decision
EMA/151867/2018 European Medicines Agency decision P/0107/2018 of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (Fasenra), (EMEA-001214-PIP01-11-M07)
More informationList of nationally authorised medicinal products
12 April 2018 EMA/243033/2018 Human Medicines Evaluation Division Active substance: fenofibrate Procedure no.: PSUSA/00001362/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationEuropean Union herbal monograph on Pistacia lentiscus L., resin (mastix)
7 July 2015 EMA/HMPC/46758/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Pistacia lentiscus L., resin (mastix) Draft Discussion in Working Party on European Union
More informationEuropean Medicines Agency decision
EMA/761887/2015 European Medicines Agency decision P/0307/2015 of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for odanacatib (EMEA- 001123-PIP01-11-M03)
More informationEuropean Medicines Agency decision
EMA/75596/2018 European Medicines Agency decision P/0076/2018 of 16 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationEuropean Medicines Agency decision
EMA/501874/2008 European Medicines Agency decision P/0303/2016 of 4 November 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationEuropean Medicines Agency decision
EMA/501681/2016 European Medicines Agency decision P/0213/2016 of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (EMEA- 001214-PIP01-11-M05)
More informationList of nationally authorised medicinal products
3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationEuropean Medicines Agency decision
EMA/348027/2017 European Medicines Agency decision P/0166/2017 of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for aciclovir (Sitavig and associated names),
More informationEuropean Medicines Agency decision
EMA/776083/2014 European Medicines Agency decision P/0001/2015 of 7 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta) (EMEA-000498-PIP01-08-M04)
More informationEuropean Union herbal monograph on Eschscholzia californica Cham., herba
28 January 2015 EMA/HMPC/680372/2013 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Eschscholzia californica Cham., herba Final Discussion in Working Party on European
More informationEuropean Medicines Agency decision
EMA/757980/2016 European Medicines Agency decision P/0313/2016 of 21 December 2016 on the agreement of a paediatric investigation plan for complex of povidone and iodine / dexamethasone (SHP640) (EMEA-001936-PIP01-16)
More informationCommission. Product. Notification. Decision. Issued 2 / affected 3 amended on 11/01/2019 PL
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
More informationEuropean Medicines Agency decision
EMA/156109/2018 European Medicines Agency decision P/0103/2018 of 19 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral for plazomicin (sulfate) (EMEA-001639-PIP02-17)
More informationEuropean Medicines Agency decision
EMA/654883/2017 European Medicines Agency decision P/0312/2017 of 30 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for cabotegravir (EMEA- 001418-PIP01-13-M01)
More informationList of nationally authorised medicinal products
12 April 2018 EMA/227889/2018 Human Medicines Evaluation Division Active substance(s): typhoid polysaccharide vaccine Procedure No.: PSUSA/00003065/201708 30 Churchill Place Canary Wharf London E14 5EU
More informationImplementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO
Implementation Report on the patient safety Recommendation 2009/C 151/01 Healthcare Systems Unit DG SANCO Published 15 November 2012 REPORT FROM THE COMMISSION TO THE COUNCIL on the basis of Member States'
More informationInterested parties (organisations or individuals) that commented on the draft document as released for consultation.
31 May 2018 EMA/CHMP/258276/2017 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Dabigatran etexilate, hard capsules, 75 mg, 110 mg and 150 mg productspecific bioequivalence
More informationList of nationally authorised medicinal products
11 September 2017 EMA/604559/2017 Human Medicines Evaluation Division Active substance: iron / parenteral preparations Procedure no.: PSUSA/00010236/201701 30 Churchill Place Canary Wharf London E14 5EU
More informationEuropean Medicines Agency decision
EMA/281879/2015 European Medicines Agency decision P/0097/2015 of 8 May 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for human
More informationEuropean Medicines Agency decision
EMA/398442/2016 European Medicines Agency decision P/0191/2016 of 15 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for agomelatine (Valdoxan, Thymanax), (EMEA-001181-PIP01-11-M03)
More informationList of nationally authorised medicinal products
11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill
More informationEUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008
European Medicines Agency Doc. Ref. EMEA/357907/2008 P/53/2008 EUROPEAN MEDICINES AGENCY DECISION of 20 July 2008 on the application for agreement of a Paediatric Investigation Plan for Atorvastatin calcium
More informationEuropean Medicines Agency decision
EMA/565636/2017 European Medicines Agency decision P/0282/2017 of 4 October 2017 on the granting of a product specific waiver for ramucirumab (Cyramza), (EMEA-002074-PIP01-16) in accordance with Regulation
More informationCHMP List of questions
28 June 2018 EMA/CHMP/346196/2018 To be addressed by the marketing authorisation holders for bacterial lysatescontaining medicinal products for respiratory conditions Referral under Article 31 of Directive
More informationEuropean Medicines Agency decision
EMA/208387/2017 European Medicines Agency decision P/0089/2017 of 6 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for melatonin (Circadin), (EMEA-000440-PIP02-11-M05)
More informationEuropean Union herbal monograph on Peumus boldus Molina, folium
22 November 2016 EMA/HMPC/453725/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Peumus boldus Molina, folium Final Initial assessment Discussion in Working Party
More informationEuropean Union herbal monograph on Ruscus aculeatus L. rhizoma
30 January 2018 EMA/188804/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Ruscus aculeatus L. rhizoma Draft Initial assessment Discussion in Working Party on European
More informationUpdate on public hearing
Update on public hearing PCWP/HCPWP joint meeting Presented by Juan Garcia Burgos on 0 September 017 Head of Public Engagement Department An agency of the European Union A public hearing provides An opportunity
More informationEuropean Medicines Agency decision
EMA/848760/2017 European Medicines Agency decision P/0033/2018 of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (Januvia), (EMEA-000470-PIP01-08-M10)
More informationQ&A on Off-Label Use. EMA Industry Stakeholder Platform - Operation of EU Pharmacovigilance Legislation 12 January 2015
Proposal in response to EFPIA paper of 3 rd October 2014 EMA Industry Stakeholder Platform - Operation of EU Pharmacovigilance Legislation 12 January 2015 Presented by Sabine Brosch (EMA) and Anja van
More informationEuropean Union herbal monograph on Glycine max (L.) Merr., lecithinum
31 January 2017 EMA/HMPC/220599/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Glycine max (L.) Merr., lecithinum Final Discussion in Working Party on European Union
More informationPrasugrel hydrochloride film-coated tablets 5 mg and 10 mg product-specific bioequivalence guidance
31 May 2018 EMA/CHMP/158772/2016/Rev.1 Committee for Medicinal Products for Human Use (CHMP) Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg Draft Agreed by Pharmacokinetics Working Party April
More informationEuropean Medicines Agency decision
EMA/731087/2017 European Medicines Agency decision P/0341/2017 of 16 November 2017 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens (haemagglutinin
More informationEuropean Medicines Agency decision
EMA/279562/2017 European Medicines Agency decision P/0129/2017 of 8 May 2017 on the acceptance of a modification of an agreed paediatric investigation plan for Split influenza virus, inactivated containing
More informationEuropean Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix
05 June 2018 EMA/HMPC/444244/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium Final Initial assessment Discussion in Working
More informationEuropean Medicines Agency decision
EMA/285017/2012 European Medicines Agency decision P/0105/2012 Of 4 June 2012 on the acceptance of a modification of an agreed paediatric investigation plan for tiotropium bromide (monohydrate) (Spiriva
More informationEuropean Medicines Agency decision
EMA/106209/2017 European Medicines Agency decision P/0074/2017 of 17 March 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationVARIATIONS : IMPACT ON ADMINISTRATIVE BURDEN AND FEES. Rose-Marie Molina EMA Infoday London, 14th March 2014
Rose-Marie Molina EMA Infoday London, 14th March 2014 Before 1234/2008 Regulation, variation procedures in the European Union for industry was synonymous of: - Lack of visibility about timelines - Lack
More informationEuropean Medicines Agency decision
EMA/137097/2017 European Medicines Agency decision P/0073/2017 of 17 March 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationEuropean Medicines Agency decision
EMA/757977/2016 European Medicines Agency decision P/0364/2016 of 21 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for KEOC liquid extract ethanolic 30 per
More informationEuropean Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba
24 November 2015 EMA/HMPC/712511/2014 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba Final Discussion
More informationCommission. Product. Notification. Decision. Issued 2 / affected 3 amended on
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
More informationEuropean Medicines Agency decision
EMA/666038/2017 European Medicines Agency decision P/0323/2017 of 31 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris), (EMEA-000876-PIP05-15-M02)
More informationEuropean Medicines Agency decision
EMA/434825/2017 European Medicines Agency decision P/0235/2017 of 9 August 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for venetoclax (Venclyxto), (EMEA-002018-PIP02-16)
More informationEuropean Union herbal monograph on Symphytum officinale L., radix
5 May 2015 EMA/HMPC/572846/2009 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Symphytum officinale L., radix Final Discussion in Working Party on Community monographs
More informationEuropean Medicines Agency decision
EMA/75416/2018 European Medicines Agency decision P/0042/2018 of 16 February 2018 on the acceptance of a modification of an agreed paediatric investigation plan for dasatinib (Sprycel), (EMEA-000567-PIP01-09-M05)
More informationInterested parties (organisations or individuals) that commented on the draft document as released for consultation.
25 January 2018 EMA/CHMP/729976/2017 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Paracetamol oral use, immediate release formulations product-specific bioequivalence
More informationEuropean Medicines Agency decision
EMA/155875/2015 European Medicines Agency decision P/0062/2015 of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (Januvia), (EMEA-000470-PIP01-08-M09)
More informationEuropean Union herbal monograph on Oenothera biennis L. or Oenothera lamarckiana L., oleum
5 June 2018 EMA/HMPC/753041/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Oenothera biennis L. or Oenothera lamarckiana L., oleum Final Discussion in Working Party
More informationNew product information wording Extracts from PRAC recommendations on signals
25 January 2018 EMA/PRAC/8436/2018 Pharmacovigilance Risk Assessment Committee (PRAC) New product information wording Extracts from PRAC recommendations on signals Adopted at the 8-11 January 2018 PRAC
More information